[Inhibition of L-arginine and cilostazol on activation of platelets in vitro].
The purpose of study was to investigate the effects of L-arginine and cilostazol on platelet-activation and aggregation reserve in vitro, so as to provide proof for selecting reversible activation-inhibitors for platelets lyophilization. Activation and function of platelets were investigated by using flow cytometry with the CD62p and PAC-1 expression and re-expression after being activated by thrombin, and by means of platelet aggregation reaction to thrombin, ADP and propyl gallate, as well as coagulation activity of platelets. The results showed that expression of CD62p and PAC-1 increased after being pretreated. Both L-arginie and cilostazol could inhibit CD62p and PAC-1 expression and related with their concentrations. Cilostazol had an intensive inhibition effect on expressions of CD62p and PAC-1 induced by thrombin, and the inhibition increased when concentration augmented. L-arginine had the same effects on PAC-1, but had no effects on CD62p. L-arginine and cilostazol inhibited aggregation induced by thrombin, ADP and propyl gallate, and the inhibitions were related directly with dosage. When L-arginine concentration was higher or equal to 15 mmol/L, or cilostazol concentration was in range of 1 - 4 mmol/L, the aggregation time were prolonged so much or even no aggregation. It is concluded that when L-Arginine concentration is 5 mmol/L and 10 mmol/L, platelet activation can be inhibited, but aggregation ability and characters keep intact. Concentration at 5 mmol/L may be the best. 1 mmol/L of cilostazol can inhibit activation in vitro and retain part of platelet ability of aggregation and reexpression.
Zhou
Jun
J
Department of Blood Transfusion, Urumqi General Hospital of Lanzhou Military Area, Urumq 830000, China.
Liu
Jing-Han
JH
Xing
Yan-Chao
YC
Wang
Dong-Mei
DM
Ouyang
Xi-Lin
XL
D001120:Arginine / Q000494:pharmacology*; D001792:Blood Platelets / Q000378:metabolism; D000077407:Cilostazol; D006801:Humans; D019007:P-Selectin / Q000187:drug effects / Q000378:metabolism; D015539:Platelet Activation / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013777:Tetrazoles / Q000494:pharmacology*
D019007:P-Selectin; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D001120:Arginine; D000077407:Cilostazol